Latest ICU news and sentiment

SeaStar Medical (ICU) Q2 2026 Earnings: Loss Narrows More Than Expected, No Revenue Still Reported - Post-Announcement Reaction

SeaStar Medical (ICU) Q2 2026 Earnings: Per-Share Loss Narrows Against Expectations Amid Development-Stage Operations - Earnings Surprise Score

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Eric SchlorffSenior Vice President of Commercial and Business Operations - Tim VaracekChief Medical Officer - Kevin ChungChief Financial Officer - Michael Messinger TAKEAWAYS Net Revenue -- $615,000 for SeaStar Medical Holding Corporation(NASDAQ:ICU), representing an 82% increase year over year driven by expanded adoption of QUELIMMUNE therapy.Six-Month Net Revenue -- $1.1 million, reflecting consistent momentum toward the full-year target of $2 million.Gross Profit Margin -- 91%, remaining consistent with the prior four quarters and reflecting pharmaceutical-like margins for the selective cytopheretic device technology.Research and Development Expenses -- $2.5 million, representing an increase from $1.0 million due to additional clinical sites and higher patient enrollment in the NEUTRALIZE-AKI study.General and Administrative Expenses -- $1.8 million, reflecting increased compensation costs, legal fees, and professional fees.Net Loss -- $3.7 million, or $0.91 per share, compared to a net loss of $2.0 million in the prior-year period.Cash and Cash Equivalents -- $7.0 million as of June 30, 2026, compared to $12.0 million at the end of 2025.Hospital Customer Base -- 20 hospitals, including top-rated children's medical centers, which represents a doubling of the customer base since the beginning of 2026.2026 Hospital Adoption Goal -- 25 hospitals, representing the company's year-end target for establishing QUELIMMUNE in the pediatric critical care market.NEUTRALIZE-AKI Enrollment -- 223 patients enrolled out of a total target of 339, with completion anticipated between the fourth quarter of 2026 and the first quarter of 2027.Monthly Patient Enrollment -- 8 to 12 patients per month, though management expects this rate to increase to 15 to 20 patients as new sites are activated.Adult Market Scale -- 50-fold larger than the pediatric market, representing the potential growth opportunity if the selective cytopheretic device is approved for adult use.ICD-10-PCS Code Implementation -- Oct. 1, 2026, which is expected to simplify hospital billing and remove administrative barriers to therapy adoption.Clinical Trial Site Expansion -- two new clinical sites onboarded recently, with four additional sites expected to begin screening patients shortly and eight more committed to participating.PMA Submission Timeline -- late 2027, remains the target for submitting the final clinical module of the modular Premarket Approval application to the FDA.C-Reactive Protein (CRP) Enrichment -- 3.5 mg/dL threshold used as enrollment criteria to ensure trial participants have sufficient inflammatory levels to demonstrate therapeutic effect.Inventory -- $77,000, representing a slight increase from $66,000 at the end of the previous fiscal year.Accounts Receivable -- $208,000, compared to $237,000 as of Dec. 31, 2025.Current Liabilities -- $4.4 million, including $3.5 million in accrued expenses and $750,000 in accounts payable.SAVE Registry Progress -- 50 patients completed in the safety registry required by the FDA to evaluate QUELIMMUNE safety in real-world pediatric settings.Primary Endpoint -- 90-day composite of mortality or dialysis dependence, established as the main metric for the NEUTRALIZE-AKI pivotal trial.Cost of Goods Sold -- $54,000 for the quarter, compared to $27,000 in the second quarter of 2025.Notes Payable -- $134,000, net of deferred financing costs, as of June 30, 2026.Weighted Average Shares Outstanding -- 4.1 million shares, compared to 1.1 million shares in the prior-year period. Need a quote from a Motley Fool analyst? Email pr@fool.com RISKS Chief Medical Officer Chung stated that monthly enrollment has averaged 8 to 12 patients, which he characterized as "slower than what I would like," though he noted that site expansion and reinforcements are expected to increase the pace to 15 to 20 subjects per month. SUM

SEASTAR MEDICAL HOLDING ($ICU) Releases Q2 2026 Earnings

SEASTAR MEDICAL HOLDING ($ICU) announced its Q2 2026 earnings, reporting -$0.91 per share, which beat estimates. The company also surpassed revenue expectations with $620,000. Following the earnings release, the stock experienced a -2.96% change after market close, and the article also details recent hedge fund activity related to ICU stock.

ICU Medical (ICUI) Following Raised 2026 Guidance Looks Modestly Undervalued

ICU Medical (ICUI) Following Raised 2026 Guidance Looks Modestly Undervalued

SeaStar Medical Holding Corp (ICU) Earnings Forecast: Future EPS & Revenue Growth Estimates

SeaStar Medical Holding Corp (ICU) has an earnings forecast score of 8.00, placing it 65th in the Healthcare Equipment & Supplies industry. Analysts have a consensus "Buy" rating for ICU with an average price target of $1.00. The company's expected revenue for the next quarter is $486.50K, and the expected EPS is -$0.97.

ICU Medical Earnings: Competitive Wins in Infusion Systems Boost 2026 Guidance